Tony Coles has degrees from Johns Hopkins, Harvard, and Duke. He’s a cardiologist by training and practiced medicine at Massachusetts General Hospital. He’s a Big Pharma veteran, having spent time in executive positions at Merck and Bristol-Myers Squibb.

But Coles is probably best known for his work in the biotech world. He led NPS Pharmaceuticals for a time, and then in early 2008, he was named CEO of Onyx Pharmaceuticals. It’s in this role that Coles really left his mark. He took over as CEO of the cancer drug maker when it was on some shaky ground with investors and its partner, the German pharma giant Bayer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy